American Association for Cancer Research
Browse
00085472can090605-sup-smethods.pdf (10.74 kB)

Supplementary Methods from Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL–Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors

Download (10.74 kB)
journal contribution
posted on 2023-03-30, 18:47 authored by Zainab Jagani, Keli Song, Jeffery L. Kutok, M. Rajan Dewar, Armelle Melet, Tanya Santos, Alexandra Grassian, Saghi Ghaffari, Catherine Wu, Ruibao Ren, Heather Yeckes Rodin, Kenneth Miller, Roya Khosravi-Far
Supplementary Methods from Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL–Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors

History

ARTICLE ABSTRACT

BCR-ABL plays an essential role in the pathogenesis of chronic myeloid leukemia (CML) and some cases of acute lymphocytic leukemia (ALL). Although ABL kinase inhibitors have shown great promise in the treatment of CML, the persistence of residual disease and the occurrence of resistance have prompted investigations into the molecular effectors of BCR-ABL. Here, we show that BCR-ABL stimulates the proteasome-dependent degradation of members of the forkhead family of tumor suppressors in vitro, in an in vivo animal model, and in samples from patients with BCR-ABL–positive CML or ALL. As several downstream mediators of BCR-ABL are regulated by the proteasome degradation pathway, we also show that inhibition of this pathway, using bortezomib, causes regression of CML-like disease. Bortezomib treatment led to inhibition of BCR-ABL–induced suppression of FoxO proteins and their proapoptotic targets, tumor necrosis factor–related apoptosis-inducing ligand and BIM, thereby providing novel insights into the molecular effects of proteasome inhibitor therapy. We additionally show sensitivity of imatinib-resistant BCR-ABL T315I cells to bortezomib. Our data delineate the involvement of FoxO proteins in BCR-ABL–induced evasion of apoptosis and provide evidence that bortezomib is a candidate therapeutic in the treatment of BCR-ABL–induced leukemia. [Cancer Res 2009;69(16):6546–55]

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC